Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

The agent security gap: 54% of enterprises have already had an AI agent incident, and most still let agents share credentials

View original at venturebeat.com
VentureBeat AI - Enterprise Ai Title: The agent security gap: 54% of enterprises have already had an AI agent incident, and most still let agents share credentials Date: 2026-07-16 19:02 Source: https://venturebeat.com/ai/the-agent-security-gap-54-of-enterprises-have-already-had-an-ai-agent-incident-and-most-still-let-…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Only about a third (32%) of enterprises give every agent its own scoped, managed identity; the rest report shared credentials somewhere in the agent fleet.

    60% confidence
  • Among organizations that have been hit by an incident, 42.1% plan to adopt, add, or replace agent security tooling within 90 days, versus 14.0% of organizations with no incident; after a confirmed incident this rises to 52.6%.

    60% confidence
  • Incident/near-miss rate rises from 49% in mid-market companies (101-1,000 employees) to 63% at larger enterprises (above 1,000 employees), while sandbox isolation falls from 35% to 20% and satisfaction drops from 4.36 to 3.97.

    60% confidence
  • Only three in ten enterprises (30%) isolate their highest-risk agents in sandboxes.

    60% confidence
  • A clear majority (59%) of enterprises intend to adopt a new, additional, or replacement agent security solution within twelve months, and 29% within the next quarter.

    60% confidence
  • More than half of organizations (54%) have already experienced a confirmed agent security incident (18%) or a near-miss caught before harm (36%).

    60% confidence
  • The most common agent security budget allocation is 6-10% (46%), a third of enterprises (34%) spend 5% or less, and only 24% spend more than a tenth.

    60% confidence
  • Organizations with credential sharing anywhere in the fleet were hit with an incident or near-miss at 63.5% (47 of 74), versus 40.9% (9 of 22) for organizations where every agent has its own scoped identity.

    60% confidence
  • Only 35% of enterprises believe their AI-enabled defenses are ahead of AI-enabled attackers; 53% rate the balance as even or tilted toward the attacker.

    60% confidence
  • Satisfaction with agent security tooling averages 4.2 out of 5 overall, and 4.1 for value for money.

    60% confidence
  • OpenAI's guardrails lead agent security tooling usage at 51%, and 82% of enterprises name a provider-native offering as their single primary security layer.

    60% confidence
  • Twelve percent of respondents include an agent-identity product anywhere in their consideration set, and this figure is essentially unchanged among credential-sharing organizations that have already had an incident.

    60% confidence

Data points we hold from this source

OpenAI · agent security tooling usage rate26 percent
OpenAI · purchase consideration rate34 percent
Anthropic · purchase consideration rate29 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
The agent security gap: 54% of enterprises have already had an AI agent incident, and most still let agents share credentials — Source | Via News | Finance Via News